Ibrexafungerp:一种新型三萜类抗真菌药
本文综述了ibrexafungerp的药理学、微生物学、药代动力学、药效学、疗效、安全性及在真菌感染治疗中的地位。Ibrexafungerp是首个三萜类抗真菌药,通过抑制1,3-β-D-葡聚糖合成发挥浓度依赖性杀菌作用,对念珠菌属(包括多数氟康唑耐药株)和曲霉属有活性。2期和3期临床试验显示其治疗白念珠菌所致外阴阴道念珠菌病安全有效,已获批用于成年及初潮后女性外阴阴道念珠菌病,妊娠期禁用。
要点
- Ibrexafungerp是首个三萜类抗真菌药,与棘白菌素结合位点不同,交叉耐药有限。
- 对念珠菌属(含多数氟康唑耐药株)和曲霉属有体外活性,呈浓度依赖性杀菌。
- 获批用于外阴阴道念珠菌病,用法为150 mg口服,两次间隔12小时,妊娠禁用。
核心结论
- Ibrexafungerp是非妊娠女性外阴阴道念珠菌病除氟康唑外的替代选择。
- 对复发性、复杂性外阴阴道念珠菌病及某些侵袭性真菌感染可能有应用前景。
研究设计与样本
- 综述总结了ibrexafungerp的药理学、微生物学、药代动力学、药效学、疗效、安全性及临床定位。
- 疗效证据来自2期和3期临床试验,针对白念珠菌所致外阴阴道念珠菌病。
主要发现
- Ibrexafungerp抑制1,3-β-D-葡聚糖合成,与棘白菌素结合位点不同,交叉耐药有限。
- 对念珠菌属呈浓度依赖性杀菌活性,对多数氟康唑耐药株保留体外活性,对曲霉属也有活性。
- 2期和3期试验显示其治疗白念珠菌所致外阴阴道念珠菌病安全有效。
- 最常见不良反应为腹泻、恶心、腹痛、头晕和呕吐。
关键数值与推荐
- 获批用于成年及初潮后女性外阴阴道念珠菌病,用法为两次150 mg片剂口服、间隔12小时。
- 妊娠期禁用。
- 应避免与强或中度CYP3A诱导剂合用,与强CYP3A抑制剂合用时需减量。
临床怎么用
- 适用于不能接受氟康唑或偏好口服治疗的外阴阴道念珠菌病患者。
- 用药前需评估妊娠状态、合并用药(尤其CYP3A诱导剂/抑制剂)及费用因素。
- 对复发性、复杂性外阴阴道念珠菌病及侵袭性念珠菌病、肺曲霉病的应用尚在临床试验中。
局限性
- Ibrexafungerp价格高于150 mg仿制氟康唑片,后者为当前外阴阴道念珠菌病标准治疗。
- 复发性、复杂性外阴阴道念珠菌病及侵袭性真菌感染的临床证据尚待试验完成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The pharmacology, microbiology, pharmacokinetics, pharmacodynamics, efficacy, safety, and role of ibrexafungerp in the treatment of fungal infections are reviewed. SUMMARY: Ibrexafungerp is the first triterpenoid antifungal. Similarly to echinocandins, it inhibits the synthesis of 1,3-β-d-glucan. However, it binds to a different site on the enzyme than echinocandins, resulting in limited cross-resistance. Ibrexafungerp exerts concentration-dependent fungicidal activity against Candida species and retains in vitro activity against most fluconazole-resistant strains. It is also active against Aspergillus species. Ibrexafungerp has been shown to be safe and effective in the treatment of vulvovaginal candidiasis caused by Candida albicans in phase 2 and phase 3 clinical trials. It is approved for vulvovaginal candidiasis in adult and postmenarchal pediatric females and is given as two 150-mg tablets orally, administered 12 hours apart. Ibrexafungerp is contraindicated in pregnancy. The most commonly reported adverse reactions were diarrhea, nausea, abdominal pain, dizziness, and vomiting. Ibrexafungerp should be avoided with strong or moderate CYP3A inducers, and the dose should be reduced with strong CYP3A inhibitors. Ibrexafungerp may be useful for patients who are not able to receive fluconazole or prefer oral therapy for the treatment of vulvovaginal candidiasis. However, it is more expensive than the 150-mg tablet of generic fluconazole, which is the current standard of care for vulvovaginal candidiasis. Clinical trials are ongoing for recurrent and complicated vulvovaginal candidiasis as well as invasive candidiasis and pulmonary aspergillosis. CONCLUSION: Ibrexafungerp is an alternative to fluconazole for the treatment of vulvovaginal candidiasis in nonpregnant females. It has the potential to be useful for recurrent and complicated vulvovaginal candidiasis as well as certain invasive fungal infections.
引用
- Sucher AJ, Thai A, Tran C, et al. Ibrexafungerp: A new triterpenoid antifungal. Am J Health Syst Pharm. 2022. PMID: 36083109. doi:10.1093/ajhp/zxac256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。